Asset Lead (Director), Oncology Outcomes Research
AstraZeneca
Summary
AstraZeneca's vision in Oncology is to help patients by redefining the cancer-treatment paradigm with the bold ambition to eliminate cancer as a cause of death. We are seeking an Asset Lead, Oncology Outcomes Research (O2R) who will report to the Tumor Lead for Oncology Outcomes Research.
Job description
What You'll Do
- Leads the development and execution of the Global Franchise strategy including real world evidence, and other activities to assess, quantify and communicate the value proposition for AZ's oncology portfolio.
- Responsible for leading the development and execution of asset specific Global and US Regional health outcomes strategy.
- Oversees a team of Outcomes Researchers, which will deliver both the strategy and technical execution of projects for that specific Franchise.
- Responsible for strategically communicating and influencing a diverse group of internal and external collaborators in GMA, OBU and ORD.
- Proactive relationship and communications with key counterparts in GMA, CMLT, USMA, EUCAN, OMAP, International.
- Will manage, coach and mentor outcomes researchers with diverse technical skills and enable them to deliver impactful and measurable results.
- Oversees the development of research plans for assets.
- Participates in key internal review and governance meetings to ensure the scientific rigor of AZ sponsored research including ERT.
Minimum Qualifications
- Minimum 5 years' experience in the pharmaceutical industry
- Expert knowledge and application of epidemiological/health outcomes methodology within pharmaceutical industry at an international level.
- In-depth expertise with research methods for real world research, HEOR projects including pharmacoepidemiologic models.
- Scientific expertise in oncology with knowledge of different data sources
- Travel-25%
Preferred Qualifications
- Graduate degree (MS, MPH, PhD) in health economics, epidemiology, outcomes research and/or related fields.
- Demonstrated expertise in analytical, judgment and problem-solving skills.
- Strong written and verbal communication skills as well as strong leadership and interpersonal skills.
- Proven ability with a track record of success in developing and leading teams
- Capable of managing budgets and resources, and shifting priorities in a rapidly changing environment
Requirements
- Minimum 5 years' experience in the pharmaceutical industry
- Expert knowledge and application of epidemiological/health outcomes methodology within pharmaceutical industry at an international level
- In-depth expertise with research methods for real world research, HEOR projects including pharmacoepidemiologic models
- Scientific expertise in oncology with knowledge of different data sources
- Travel-25%
- Graduate degree (MS, MPH, PhD) in health economics, epidemiology, outcomes research and/or related fields
- Demonstrated expertise in analytical, judgment and problem-solving skills
- Strong written and verbal communication skills as well as strong leadership and interpersonal skills
- Proven ability with a track record of success in developing and leading teams
- Capable of managing budgets and resources, and shifting priorities in a rapidly changing environment
Benefits
- Health Insurance
- Dental Coverage
- Vision Coverage
- Retirement Programs
- Paid Time Off
- Short-Term Incentive Bonuses
- Equity-Based Awards
Company overview
AstraZeneca is a global, science-led, patient-focused pharmaceutical company dedicated to accelerating the delivery of life-changing medicines that create enduring value for patients, society, and shareholders. With a workforce of over 94,300 employees worldwide, the company operates across three core therapy areas: Oncology, BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, Respiratory & Immunology), and Rare Disease. Headquartered in Cambridge, UK, AstraZeneca maintains strategic R&D centers in Cambridge, Gaithersburg (US), Boston (US), Gothenburg (Sweden), Shanghai, and Beijing. The company generated $54.1 billion in total revenue in 2024 and invested $13.6 billion in scientific research and development. AstraZeneca's bold aspiration is to be pioneers in science, lead in disease areas, and transform patient outcomes, with a goal to launch 20 new medicines and achieve $80 billion in total revenue by 2030. The company is recognized for its commitment to sustainability, health equity, and creating an inclusive work environment where diverse perspectives drive innovation.